Pheast Therapeutics revealed the initial showcasing of preclinical data for PHST001, an anti-CD24 antibody drug candidate.

May 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Azitra, Inc. Reveals Encouraging Preclinical Data on ATR-12 and Clinical Plan for Netherton Syndrome at ASGCT Annual Conference.

Eisai Begins Submission of Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) Subcutaneous Maintenance Dosing in Early Alzheimer's, Fast Track Status.

PTC Therapeutics, Inc. revealed today that the FDA has officially received the Biologics License Application for Upstaza™ (eladocagene exuparvovec), a gene therapy aimed at treating AADC deficiency.

Verismo Therapeutics announced that the FDA has approved a Phase 1 clinical trial for SynKIR™-310 to evaluate its effectiveness for NHL.

This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.

Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.

The data reveal that the experimental AZR-MD-001 has shown lasting effects in enhancing the ocular symptoms of Meibomian Gland Dysfunction (MGD) after a six-month treatment period.

The innovative gene therapy ABBV-RGX-314 is poised to set a new benchmark in the treatment of wet age-related macular degeneration (AMD).

Ocean Biomedical has expressed its congratulations to its joint venture (JV) partner, Virion Therapeutics.

The proceeds from this offering will fund Stoke's R&D activities, especially for their Dravet syndrome candidate STK-001, preclinical development of ophthalmology candidate STK-002, and other pipeline projects.